Pricing Log in Create free account

Impact Biomedical Inc. (IBO) vs TransCode Therapeutics Inc. (RNAZ)

Impact Biomedical Inc. and TransCode Therapeutics Inc. are both Biotechnology companies. TransCode Therapeutics Inc. is the larger, with a market value of $30.5M against $27.0M — 1.1× the size. TransCode Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; Impact Biomedical Inc. trades at 0.2×. Impact Biomedical Inc. has the higher net margin (2,254.3% vs 0.00%) and the lower return on invested capital (−22.8% vs 0.00%). Across the 12 metrics below, TransCode Therapeutics Inc. leads on 7 and Impact Biomedical Inc. on 5.

Valuation

Metric IBO RNAZ Biotechnology median
P/E 0.24 n/m 8.50
P/S 653.87 n/m 9.71
P/B 1.63 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.10 0.64
EV/Sales 881.33 n/m 9.21
Earnings yield 415.59% (3,080.59%) (33.15%)
Free cash flow yield (2.30%) (1,390.70%) (25.50%)

Profitability

Metric IBO RNAZ Biotechnology median
Gross margin (1,111.43%) 0.00% 65.16%
Operating margin (14,600.00%) 0.00% 0.00%
Net margin 2,254.29% 0.00% 0.00%
Free cash flow margin (1,451.43%) 0.00% 0.00%
Return on equity 24.01% 429.61% (56.36%)
Return on assets 4.41% (58.12%) (48.04%)
Return on invested capital (22.81%) 0.00% 0.00%

Growth

Metric IBO RNAZ Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 83.48% 96.02% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric IBO RNAZ Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.16 1.97 4.72
Net debt to EBITDA 0.00 0.64 0.96

Dividend

Metric IBO RNAZ Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric IBO RNAZ Biotechnology median
Market cap 26.99m 30.48m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack